🔗 Share this article

The recently developed medications for gonorrhoea in decades are being described as a "huge turning point" in the effort against increasingly resistant strains of the bacteria, according to researchers.

An International Public Health Issue

The sexually transmitted infection are increasing around the world, with figures suggesting over 82 million infections each year. Especially elevated rates are observed in Africa and countries within the World Health Organization's designated area, which includes China and Mongolia to New Zealand. Across England, cases have reached a all-time high, while infection numbers across Europe in 2023 were three times higher compared to figures for 2014.

“The clearance of new treatments for gonorrhoea is an critical and opportune development in the face of growing infection rates, escalating drug resistance and the very limited therapeutic options at this time.”

Public health authorities are deeply concerned about the surge in drug-resistant strains. The WHO has designated it as a "high-priority threat". A tracking program revealed that the effectiveness of primary antibiotics like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

A Pair of Novel Drugs Secure Approval

Zoliflodacin, marketed under the name Nuzolvence, was authorized by the American regulatory agency in recent days for use against gonorrhoea. This disease can lead to serious health problems, including infertility. Experts believe that focused deployment of this new drug will help slow the spread of drug resistance.

Another new antibiotic, originating from the drugmaker GlaxoSmithKline, was also approved in concurrent days. This treatment, which is also used to treat urinary tract infections, was shown in trials to be effective against drug-resistant strains of the gonorrhoea bacteria.

A Unique Partnership

Zoliflodacin was the result of a new, not-for-profit approach for antibiotic development. The charitable organization Global Antibiotic Research & Development Partnership worked alongside the drug firm its industry partner to see it through.

“This approval represents a huge turning point in the management of superbug gonorrhoea, which until now has been outpacing antibiotic development.”

Testing Outcomes and Global Access

Based on data released by a major medical journal, zoliflodacin eradicated over nine in ten of genital gonorrhoea infections. This places it at an comparable level with the current standard treatment, which uses a dual-drug approach. The study included nearly 1,000 patients from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its unique model, GARDP has the authority to license and sell the drug in a wide range of low-income and middle-income countries.

Medical professionals on the front lines have expressed optimism. Having a single-dose, oral treatment such as this is described as a "revolutionary step" for gonorrhoea control. This is viewed as vital to reduce the burden of the infection for patients and to halt the transmission of untreatable gonorrhoea globally.